Listed as number three in pharma sales, GlaxoSmithKline has had some rough luck thanks in part to the diabetes drug Avandia, which has been pulled out of Europe and restricted in the U.S after global side effect concerns since 2007. The company cut its losses on the drug, writing off $233 million in supplies and eliminating its marketing efforts of the drug.

The company has racked up some charges against its earnings, including over $6 billion in the fourth quarter of 2010 from Avandia and marketing settlements. GSK settled 10,000 Avandia lawsuits for a combined $460 million. Also, the company hit number three on FiercePharma's Top Layoffs of 2010 list with 5,201 jobs lost. While other companies look towards more spinoffs, GSK has focused on emerging markets as its ticket to higher revenue. It purchased Laboratorios Phoenix in 2009 and China's MeiRui in 2010; the UK-based company said the impact of its layoffs would be masked by more job opportunities in Asia and South America.

In early 2011, GSK and Human Genome Sciences gained FDA approval for Benlysta, the first new lupus treatment in more than 50 years, and experts believe it could be a $3 billion to $5 billion worldwide sales heyday for the partnership. But the FDA denied an extended approval and a potential $1 billion in sales to GSK from the prostate drug Avodart. While the drug was effective against low-risk malignant tumors, it potentially heightened the risk of developing more aggressive tumors.

GSK spun off its HIV treatments into ViiV Healthcare in 2009, combining it with Pfizer's former R&D efforts in the field. ViiV markets Ziagen, Trizivir, Epzicom and abacavir as part of its suite of drugs for HIV/AIDS.

Tag:

GlaxoSmithKline

Latest Headlines

Latest Headlines

Gilead's Sovaldi, GSK's Anoro stand out in 2014's blockbuster crop, report says

Want to take a guess about which three new drugs are marked for greatness in 2014? One of them is obvious. Another, not so much. And the third isn't approved yet.

GlaxoSmithKline and Galapagos succeed in psoriasis after two setbacks

Galapagos and partner GlaxoSmithKline say their anti-inflammation candidate hit its mark in a mid-stage trial on psoriasis, a stroke of good news for a drug beset by developmental slipups.

GlaxoSmithKline steps up bribery probes, eyeing potential violations in 9 Middle Eastern countries

GlaxoSmithKline has added two more countries to its bribery-investigation list. The U.K.-based drugmaker now says it faces probes in Jordan and Lebanon, in addition to recently announced investigations in Iraq and Poland.

GlaxoSmithKline's new diabetes med faces formidable GLP-1 foes

GlaxoSmithKline's albiglutide, now dubbed Tanzeum for the U.S. market, nabbed FDA approval Tuesday.

GlaxoSmithKline bribery probe heats up as Polish prosecutors charge 13 people

Polish prosecutors have charged 13 people in connection with the GlaxoSmithKline bribery probe in their country.

Newly minted GlaxoSmithKline diabetes drug faces formidable foes in GLP-1 market

GlaxoSmithKline's albiglutide, now dubbed Tanzeum for the U.S. market, nabbed FDA approval Tuesday. Now, the drug will go up against a triad of other GLP-1 treatments, including Novo Nordisk's powerhouse Victoza and AstraZeneca's exanatide franchise.

GlaxoSmithKline wins an FDA nod for its GLP-1 diabetes drug albiglutide

After a three-month delay pushed pause on its commercial plans, GlaxoSmithKline has secured FDA approval for albiglutide, a new diabetes treatment that will contend for market share in a fast-crowding space.

Polish prosecutors hit GlaxoSmithKline with third round of bribery charges

GlaxoSmithKline has now hit a trifecta in bribery investigations: First China, then Iraq, and now, Poland. According to the BBC, a former GSK sales rep says the company was trading cash for prescriptions in the country in a wink-wink sort of way, by disguising the script incentives as speaking fees.

Impax gives it another go with a once-rejected Parkinson's drug

After a manufacturing problem irked the FDA and scared off partner GlaxoSmithKline, Impax Laboratories is resubmitting its investigational drug for Parkinson's disease, hoping it can clear an agency inspection and finally get its treatment on the market.

Report: Emergency flu vaccine manufacturing site will be online by 2017

One of three manufacturing sites commissioned by the Department of Health and Human Services to quickly develop and produce flu vaccines in the case of a pandemic is expected to be fully operational by 2017, officials say.